XOMA Royalty Appoints Biotech Veteran Jeffrey Trigilio as New CFO
Summary
XOMA Royalty appointed Jeffrey Trigilio, an experienced biotech finance executive, as its new Chief Financial Officer, succeeding long-serving CFO Thomas Burns.
Key Events
-
New CFO Appointed
Jeffrey Trigilio, with prior CFO roles at Obsidian Therapeutics and Cullinan Therapeutics, was appointed Chief Financial Officer, effective January 12, 2026.
-
CFO Compensation Package
Mr. Trigilio will receive an annual base salary of $515,000, a target annual cash bonus of 40% of his base salary, an initial grant of 30,000 performance units, and an annual equity grant valued at approximately 180,000 shares.
-
Departure of Previous CFO
Thomas Burns stepped down as Senior Vice President, Finance and Chief Financial Officer, effective January 12, 2026, after nearly two decades of service.
-
Transition Agreement
Mr. Burns entered into a separation and consulting agreement, receiving severance benefits and providing advisory services for three months.
Analysis
XOMA Royalty Corporation announced a significant leadership transition with the appointment of Jeffrey Trigilio as its new Chief Financial Officer, effective January 12, 2026. Mr. Trigilio brings extensive experience from various leadership roles at other biotechnology companies, including Obsidian Therapeutics and Cullinan Therapeutics. His compensation package includes a substantial annual equity grant, reflecting the company's commitment to attracting experienced talent. This change is important for the company's financial strategy and operational execution as it continues to grow its royalty aggregation business.
At the time of this filing, XOMA was trading at $26.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $326.5M. The 52-week trading range was $18.35 to $39.92. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.